Cargando…

A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer

The efficacy of anti-angiogenic agents (AAAs) in epithelial ovarian cancer (EOC) remains unclear. Therefore, we conducted a systematic review and network meta-analysis (NMA) to synthesize evidence of their comparative effectiveness for improving overall survival (OS) among EOC patients. We searched...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helali, Aya El, Wong, Charlene H. L., Choi, Horace C. W., Chan, Wendy W. L., Dickson, Naomi, Siu, Steven W. K., Chan, Karen K., Ngan, Hextan Y. S., Ngan, Roger K. C., Kennedy, Richard D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907284/ https://www.ncbi.nlm.nih.gov/pubmed/35264616 http://dx.doi.org/10.1038/s41598-022-07731-1

Ejemplares similares

Molecular Biomarkers for the Early Detection of Ovarian Cancer
por: Zhang, Ruiqian, et al.
Publicado: (2022)

Aberrant Cholesterol Metabolism in Ovarian Cancer: Identification of Novel Therapeutic Targets
por: He, Jiangnan, et al.
Publicado: (2021)

Orchestrated Action of AMPK Activation and Combined VEGF/PD-1 Blockade with Lipid Metabolic Tunning as Multi-Target Therapeutics against Ovarian Cancers
por: Yung, Mingo M. H., et al.
Publicado: (2022)

New Insights into Ferroptosis Initiating Therapies (FIT) by Targeting the Rewired Lipid Metabolism in Ovarian Cancer Peritoneal Metastases
por: Zhan, Shijie, et al.
Publicado: (2022)

Tumour Suppressive Function and Modulation of Programmed Cell Death 4 (PDCD4) in Ovarian Cancer
por: Wei, Na, et al.
Publicado: (2012)

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report
por: Ngu, Siew-Fei, et al.
Publicado: (2022)

Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer
por: Liu, Michelle X., et al.
Publicado: (2013)

The Stress-Inducible BCL2A1 Is Required for Ovarian Cancer Metastatic Progression in the Peritoneal Microenvironment
por: Liang, Rui, et al.
Publicado: (2021)

Over-expressions of AMPK subunits in ovarian carcinomas with significant clinical implications
por: Li, Cuilan, et al.
Publicado: (2012)

PFKFB3 Regulates Chemoresistance, Metastasis and Stemness via IAP Proteins and the NF-κB Signaling Pathway in Ovarian Cancer
por: Jiang, Yu-xin, et al.
Publicado: (2022)

Increased Expression of PITX2 Transcription Factor Contributes to Ovarian Cancer Progression
por: Fung, Frederic K. C., et al.
Publicado: (2012)

Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer
por: Chan, Karen K. L., et al.
Publicado: (2018)

The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
por: Wang, Huogang, et al.
Publicado: (2021)

Aberrant Activation of ERK/FOXM1 Signaling Cascade Triggers the Cell Migration/Invasion in Ovarian Cancer Cells
por: Lok, Gabriel T. M., et al.
Publicado: (2011)

Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

Correction: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer
por: Li, Cuilan, et al.
Publicado: (2014)

Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
por: Chan, David W., et al.
Publicado: (2012)

Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis
por: Mo, Yulan, et al.
Publicado: (2023)

Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis
por: Chan, Karen K. L., et al.
Publicado: (2017)

Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

Germline PALB2 Mutation in High-Risk Chinese Breast and/or Ovarian Cancer Patients
por: Kwong, Ava, et al.
Publicado: (2021)

Correction to: Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers
por: Chan, David W., et al.
Publicado: (2021)

Patient-Initiated Follow-Up in Ovarian Cancer
por: Luk, Hiu Mei, et al.
Publicado: (2023)

PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8 signaling
por: Siu, Michelle K. Y., et al.
Publicado: (2020)

Combat against cervical cancer-challenges in Asia Oceania: 5th Biennial Conference of the Asia Oceania Research Organization on Genital Infections & Neoplasia (AOGIN)
por: Ngan, Hextan YS
Publicado: (2012)

Epigenetic Silencing of miR-33b Promotes Peritoneal Metastases of Ovarian Cancer by Modulating the TAK1/FASN/CPT1A/NF-κB Axis
por: Wang, Xueyu, et al.
Publicado: (2021)

Hexokinase 2 Regulates Ovarian Cancer Cell Migration, Invasion and Stemness via FAK/ERK1/2/MMP9/NANOG/SOX9 Signaling Cascades
por: Siu, Michelle K. Y., et al.
Publicado: (2019)

Elevated TAK1 augments tumor growth and metastatic capacities of ovarian cancer cells through activation of NF-κB signaling
por: Cai, Patty C.H., et al.
Publicado: (2014)

Down-regulation of Sox7 is associated with aberrant activation of Wnt/β-catenin signaling in endometrial cancer
por: Chan, David W, et al.
Publicado: (2012)

The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells
por: Leung, T H-Y, et al.
Publicado: (2013)

TAp73-Mediated the Activation of C-Jun N-Terminal Kinase Enhances Cellular Chemosensitivity to Cisplatin in Ovarian Cancer Cells
por: Zhang, Pingde, et al.
Publicado: (2012)

Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome
por: Siu, Michelle K. Y., et al.
Publicado: (2012)

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature
por: Ngan, Roger K. C.
Publicado: (2023)

A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
por: Wang, Jing-Jing, et al.
Publicado: (2021)

SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells
por: Xuan, Yang, et al.
Publicado: (2022)

HPV Vaccination Intentions of Female Students in Chinese Universities: A Systematic Literature Review and Meta-Analysis
por: Bai, Yiming, et al.
Publicado: (2022)

Metabolic active peritoneal sites affect tumor debulking in ovarian and peritoneal cancers
por: Tsoi, Tung Tung, et al.
Publicado: (2020)

Nuclear HKII-P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer
por: Han, Chae Young, et al.
Publicado: (2021)

Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade
por: Yung, Mingo M. H., et al.
Publicado: (2015)

Overexpression of proto-oncogene FBI-1 activates membrane type 1-matrix metalloproteinase in association with adverse outcome in ovarian cancers
por: Jiang, LiLi, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_h8v80d3lqej59dqnaaefab5lv2